Protagonist Therapeutics, Inc. (PTGX) Stock Overview
NASDAQ · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis;…
Source: Yahoo Finance
Sector & Industry
Protagonist Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NASDAQ exchange.
Protagonist Therapeutics, Inc. at a Glance
| Company | Protagonist Therapeutics, Inc. |
| Ticker | PTGX |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $145.72 |
| Market cap | $9.43B |
| P/E ratio (trailing) | 141.48 |
| EPS (trailing) | $1.03 |
| 52-week high | $160.81 |
| 52-week low | $54.50 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 1.79 |
| Return on equity (ROE) | 10.98% |
| Debt-to-equity | 1.09% |
| Average volume | 668,847 |
| Shares outstanding | 64.71M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 141 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Frequently Asked Questions
- What is Protagonist Therapeutics, Inc.'s current P/E ratio?
- Protagonist Therapeutics, Inc. (PTGX) has a trailing P/E ratio of 141.48 as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Protagonist Therapeutics, Inc.'s market capitalisation?
- Protagonist Therapeutics, Inc.'s market cap is $9.43B based on our latest snapshot. See how it ranks by market cap →
- What is PTGX's 52-week range?
- Over the past 52 weeks, PTGX has traded between $54.50 and $160.81. What does the 52-week range mean? →
- How volatile is Protagonist Therapeutics, Inc. compared to the market?
- Protagonist Therapeutics, Inc. has a beta of 1.79, meaning it has historically moved more than the broader market. What does beta measure? →
- Does Protagonist Therapeutics, Inc. pay a dividend?
- Protagonist Therapeutics, Inc. does not currently pay a dividend according to our latest data.
- What exchange is PTGX listed on?
- PTGX is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Protagonist Therapeutics, Inc. in?
- Protagonist Therapeutics, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Working out potential returns or position sizes? Our payout and odds calculators handle the maths.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →Philip Fisher on what makes a business worth owning for the long term.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →